wild ace jili download free
Opposition fighters are closing in on Syria’s capital in a swiftly developing crisis that has taken much of the world by surprise. Syria's army has abandoned key cities in the west and south with little resistance. Nervous residents in Damascus describe security forces on the streets. The state news agency has been forced to deny rumors that President Bashar Assad has left the country. Who are these opposition fighters ? If they enter Damascus after taking two of Syria’s largest cities , what then? Here’s a look at the stunning reversal of fortune for Assad and his government in just the past 10 days, and what might lie ahead as Syria’s 13-year civil war reignites . This is the first time that opposition forces have reached the outskirts of the Syrian capital since 2018, when the country’s troops recaptured the area following a yearslong siege. The approaching fighters are led by the most powerful insurgent group in Syria, Hayat Tahrir al-Sham , or HTS, along with an umbrella group of Turkish-backed Syrian militias called the Syrian National Army. Both have been entrenched in the northwest. They launched the shock offensive on Nov. 27 with gunmen capturing Aleppo, Syria’s largest city, and the central city of Hama, the fourth largest. The HTS has its origins in al-Qaida and is considered a terrorist organization by the U.S. and the United Nations. But the group said in recent years it cut ties with al-Qaida, and experts say HTS has sought to remake itself in recent years by focusing on promoting civilian government in their territory as well as military action. HTS leader Abu Mohammed al-Golani told CNN in an exclusive interview Thursday from Syria that the aim of the offensive is to overthrow Assad’s government. The HTS and Syrian National Army have been allies at times and rivals at times, and their aims might diverge. The Turkish-backed militias also have an interest in creating a buffer zone near the Turkish border to keep away Kurdish militants at odds with Ankara. Turkey has been a main backer of the fighters seeking to overthrow Assad but more recently has urged reconciliation, and Turkish officials have strongly rejected claims of any involvement in the current offensive. Whether the HTS and the Syrian National Army will work together if they succeed in overthrowing Assad or turn on each other again is a major question. While the flash offensive against Syria’s government began in the north, armed opposition groups have also mobilized elsewhere. The southern areas of Sweida and Daraa have both been taken locally. Sweida is the heartland of Syria’s Druze religious minority and had been the site of regular anti-government protests even after Assad seemingly consolidated his control over the area. Daraa is a Sunni Muslim area that was widely seen as the cradle of the uprising against Assad’s rule that erupted in 2011. Daraa was recaptured by Syrian government troops in 2018, but rebels remained in some areas. In recent years, Daraa was in a state of uneasy quiet under a Russian-mediated ceasefire deal. And much of Syria's east is controlled by the Syrian Democratic Forces, a Kurdish-led group backed by the United States that in the past has clashed with most other armed groups in the country. Syria’s government now controls just four of 14 provincial capitals. Much depends on Assad’s next moves and his forces' will to fight. A commander with the insurgents, Hassan Abdul-Ghani, posted on the Telegram messaging app that opposition forces have started carrying out the “final stage” of their offensive by encircling Damascus. The Britain-based Syrian Observatory for Human Rights said Syrian troops have withdrawn from much of the two southern provinces and are sending reinforcements to Homs. If that city is captured, the link would be cut between Damascus, Assad’s seat of power, and the coastal region where he enjoys wide support. “Homs to the coastal cities will be a very huge red line politically and socially. Politically, if this line is crossed, then we are talking about the end of the entire Syria, the one that we knew in the past,” said a Damascus resident, Anas Joudeh. Assad appears to be largely on his own as allies Russia and Iran are distracted by other conflicts and the Lebanon-based Hezbollah has been weakened by its war with Israel, now under a fragile ceasefire. The U.N. special envoy for Syria, Geir Pedersen, is calling for urgent talks in Geneva to ensure an “orderly political transition,” saying the situation is changing by the minute. He met with foreign ministers and senior diplomats from eight key countries including Saudi Arabia, Russia, Egypt, Turkey and Iran on the sidelines of the Doha Summit. President-elect Donald Trump in his first extensive comments on the developments in Syria said the besieged Assad didn’t deserve U.S. support to stay in power. “THIS IS NOT OUR FIGHT,” Trump posted on social media.
The S&P 500 edged up by 2 points, or less than 0.1%, to set an all-time high for the 55th time this year. It's climbed in 10 of the last 11 days and is on track for one of its best years since the turn of the millennium. The Dow Jones Industrial Average slipped 76 points, or 0.2%, while the Nasdaq composite added 0.4% to its own record set a day earlier. AT&T rose 4.6% after it boosted its profit forecast for the year. It also announced a $10 billion plan to send cash to its investors by buying back its own stock, while saying it expects to authorize another $10 billion of repurchases in 2027. On the losing end of Wall Street was U.S. Steel, which fell 8%. President-elect Donald Trump reiterated on social media that he would not let Japan's Nippon Steel take over the iconic Pennsylvania steelmaker. Nippon Steel announced plans last December to buy the Pittsburgh-based steel producer for $14.1 billion in cash, raising concerns about what the transaction could mean for unionized workers, supply chains and U.S. national security. Earlier this year, President Joe Biden also came out against the acquisition. Tesla sank 1.6% after a judge in Delaware reaffirmed a previous ruling that the electric car maker must revoke Elon Musk's multibillion-dollar pay package. The judge denied a request by attorneys for Musk and Tesla's corporate directors to vacate her ruling earlier this year requiring the company to rescind the unprecedented pay package. All told, the S&P 500 rose 2.73 points to 6,049.88. The Dow fell 76.47 to 44,705.53, and the Nasdaq composite gained 76.96 to 19,480.91. In the bond market, Treasury yields held relatively steady after a report showed U.S. employers were advertising slightly more job openings at the end of October than a month earlier. Continued strength there would raise optimism that the economy could remain out of a recession that many investors had earlier worried was inevitable. The yield on the 10-year Treasury rose to 4.23% from 4.20% from late Monday. Yields have seesawed since Election Day amid worries that Trump's preferences for lower tax rates and bigger tariffs could spur higher inflation along with economic growth. But traders are still confident the Federal Reserve will cut its main interest rate again at its next meeting in two weeks. They're betting on a nearly three-in-four chance of that, according to data from CME Group. Lower rates can give the economy more juice, but they can also give inflation more fuel. The key report this week that could guide the Fed's next move will arrive on Friday. It's the monthly jobs report, which will show how many workers U.S. employers hired and fired during November. It could be difficult to parse given how much storms and strikes distorted figures in October. Based on trading in the options market, Friday's jobs report appears to be the biggest potential market mover until the Fed announces its next decision on interest rates Dec. 18, according to strategists at Barclays Capital. In financial markets abroad, the value of South Korea's currency fell 1.1% against the U.S. dollar following a frenetic night where President Yoon Suk Yeol declared martial law and then later said he'd lift it after lawmakers voted to reject military rule. Stocks of Korean companies that trade in the United States also fell, including a 1.6% drop for SK Telecom. Japan's Nikkei 225 jumped 1.9% to help lead global markets. Some analysts think Japanese stocks could end up benefiting from Trump's threats to raise tariffs, including for goods coming from China. Trade relations between the U.S. and China took another step backward after China said it is banning exports to the U.S. of gallium, germanium, antimony and other key high-tech materials with potential military applications. The counterpunch came swiftly after the U.S. Commerce Department expanded the list of Chinese technology companies subject to export controls to include many that make equipment used to make computer chips, chipmaking tools and software. The 140 companies newly included in the so-called "entity list" are nearly all based in China. In China, stock indexes rose 1% in Hong Kong and 0.4% in Shanghai amid unconfirmed reports that Chinese leaders would meet next week to discuss planning for the coming year. Investors are hoping it may bring fresh stimulus to help spur growth in the world's second-largest economy. In France, the CAC 40 rose 0.3% amid continued worries about politics in Paris, where the government is battling over the budget.Pete Hegseth's mother says The New York Times made 'threats' by asking her to comment on a story
Prediction: This Spectacular Artificial Intelligence (AI) Stock Will Be Worth More Than Palantir by 2030
Geoffrey Deuel, best known for portraying famed outlaw Billy the Kid in the 1970 John Wayne vehicle Chisum , died Dec. 22 at age 81, per an official obituary . The news was additionally confirmed to The Hollywood Reporter by wife Jacqueline Deuel. The performer, younger brother to Peter Duel (who became known for portraying Hannibal Heyes/Joshua Smith on the popular ABC Western Alias Smith and Jones prior to his suicide), died in hospice care in Florida following a battle with chronic obstructive pulmonary disease. “He and Peter were very close,” Jacqueline Deuel told THR . “They really loved each other and took care of each other.” Deuel, who was born Jan. 17, 1943, mostly appeared on television in a variety of series stretching from the late ’60s to mid-’70s. Among those credits are The Monkees , The Invaders , The F.B.I. , The Manhunter , Medical Center , Barnaby Jones, Mannix , Adam-12 , The Mod Squad , Mission: Impossible , The Streets of San Francisco , Ironside , Cannon , The Young and the Restless , To Rome With Love and more. Born in Lockport, New York to a doctor father and nurse mother, he was raised in nearby Penfield. After attending Penfield High School, Ithaca College and Syracuse University, Deuel followed in his brother’s footsteps, beginning his career in Hollywood in 1965. The following year, he appeared in an episode of ABC’s 12 O’Clock High . Deuel and Duel, who was three years his senior, worked alongside one another on a 1971 episode of NBC’s The Name of the Game . In the 1980s, Deuel acted in plays in Tampa, Fla. and returned to higher education to earn a master’s degree from the University of South Florida. Thereafter, he became a substitute teacher. He is survived by his wife — whom he married in 2017 after four decades together — and younger sister Pamela.De'Vondre Campbell's mid-game quitting overshadowed the 49ers' offensive woesIt's usually not difficult to find a compelling growth stock to step into. Choosing a growth stock you're confident holding onto for a decade or more, however, is a different story. Some story stocks just don't have enough proven potential for investors to make a long-term commitment to them. Are You Missing The Morning Scoop? Wake up with Breakfast news in your inbox every market day. Sign Up For Free » Still, investments that fit that bill are out there. If you can stomach the risk, these three stocks have the potential to be monster winners for investors who buy and hold for at least 10 years. Iovance Biotherapeutics Investing in drug companies can be a tricky business. If you dive in too early, you may learn the hard way that the potential miracle drug in development is actually a bust. If you wait too long, you could miss out on the bulk of a stock's gains. With that in mind, risk-tolerant investors should look at Iovance Biotherapeutics (NASDAQ: IOVA) while shares are still down more than 80% from their early 2021 peak. Such pullbacks aren't particularly unusual for the biopharma industry's younger names. Iovance soared when its flagship drug first started showing promise in clinical trials back in 2019 and 2020. Investors got a bit ahead of themselves though. The first regulatory approval of its cancer-fighting Amtagvi didn't materialize until February of this year. While the market rewarded the company for that accomplishment with a bounce in the share price, most of the bullish euphoria had already worn off by then. And most of the gains the stock booked earlier this year have since evaporated. But you can use the stock's current weakness to your advantage. While Amtagvi's FDA-approved uses may be relatively narrow in scope right now -- it is approved only for the treatment of certain types of solid tumors -- this T-cell therapy is a potential treatment for a much wider range of cancers. The drug is being tested in 12 other clinical trials at this time, and a handful of them are promising late-stage trials. But even without any future approvals, Iovance is already doing pretty well with Amtagvi. Last quarter's $58.6 million in revenue was a marked improvement on what was effectively inaugural revenue of $31.1 million in Q2, putting the company en route to a full-year top line of roughly $160 million. Sales next year are expected to rise to between $450 million and $475 million. That's just the beginning though. The analyst community is predicting revenue of more than $700 million in 2026, while research outfit GlobalData believes annual sales of Amtagvi could eclipse $1 billion by 2030. There are risks for investors to keep in mind, though. Chief among them is the massive amount of money Iovance is still losing despite strong initial demand for its flagship T-cell therapy. Although there's nothing unusual about early losses within the biopharma industry, there's no clear picture as to when the company will work its way out of the red and into the black. Even analysts don't anticipate an actual profit until 2027 at the earliest. Much can happen between now and then, so you want to carefully consider the size of any position in this stock. Amtagvi needs time to reach its proverbial cruising speed, so the challenge for investors will be having the patience to allow Iovance to make the most of the opportunity. Palo Alto Networks As long as there are internet-connected computers and networks, there will be criminals looking to digitally exploit them. Indeed, cybersecurity outfit Check Point Software reports that weekly cyberattacks surged a record-breaking 75% year over year during the third quarter, up from Q2's 30% increase. This problem isn't going away anytime soon, but Palo Alto Networks (NASDAQ: PANW) stands ready to answer the call. In simplest terms, Palo Alto helps enterprises of all shapes and sizes protect themselves from cybercrime and other types of digital disruption. From threat detection to malware defense to phishing protection to remote employee logins (and more), this company can meet almost any cybersecurity need. And it can do so with easy-to-use turnkey solutions that allow for a minimal number of user interfaces. That's one of the reasons why, in 2024, Palo Alto was once again ranked by technology market research outfit Gartner as a leader in the endpoint protection platform market. Moreover, for the eleventh year in a row, Gartner rated Palo Alto as a leader in the network firewall market. The company is good at what it does. This is evident in its fiscal results too. Not only has its revenue grown in every quarter for more than a decade, but its operating income and EBITDA (earnings before interest, taxes, depreciation, and amortization) have grown almost as reliably. Then, there's the detail about this progress that isn't readily apparent: Palo Alto Networks' profit margins are expanding too. Whether its software is sold to 100 customers or 1,000, the cost of coding and deploying it is about the same. That's the power of scale. The recurring revenue it books from subscription-based access to its tools doesn't hurt either. Palo Alto is positioned to capitalize on growth across the cybersecurity industry as analysts expect the company to deliver 14% top-line growth in its fiscal 2025 before accelerating to nearly 16% the following year. Wolfspeed Finally, add Wolfspeed (NYSE: WOLF) to your list of potential monster stocks that you may want to hold onto for the next 10 years. Unless you're an electrical engineer, the term "silicon carbide" probably won't mean much to you. It will in the foreseeable future, though, and Wolfspeed will have its time in the spotlight as a result. The layman's explanation: Nearly all electrically powered devices require the use of at least some silicon-based components. In the past, ordinary silicon was entirely good enough to meet the needs of the technology of the times. Things are changing, though. Thanks to dramatic improvements in other technologies, the silicon of yesteryear is no longer power-efficient enough, nor capable of efficiently handling the higher voltages needed by heavy-duty equipment like electric vehicles or data center power platforms. Enter Wolfspeed, which has mastered (and patented) the art and science of adding carbon to silicon to make the material more efficient as well as capable of handling higher electrical loads. While its potential uses are vast, silicon carbide's most practical application today is on the heavy machinery and industrial front. Wolfspeed's technology is increasingly found in electric vehicles as part of their powertrains as well as within their charging apparatuses, leading to 80% less power loss than most commonly used battery/inversion/motor combinations currently suffer. You'll also find its tech inside a growing number of construction vehicles, agricultural machinery, and even locomotives. At the other end of the size scale, you'll find its silicon carbide inside the chips and components attached to circuit boards in HVAC equipment and data center power supplies, where its offerings can achieve up to 99% energy efficiency at half the size of ordinary silicon. Although the benefits of silicon carbide are clear, not every would-be customer is consistently on board with Wolfspeed's products. After its revenue rose by 24% in fiscal 2023 (ended June 2023) growth came to a near-halt in fiscal 2024, extending a pattern of top-line inconsistency that's been frustrating investors for over a decade. Wolfspeed is reporting steep losses as a result. The analyst community doesn't see net profitability returning until fiscal 2027 when the next generation of EVs hits the roads and when the company finally puts several restructuring charges and significant capital expenditures in the rearview mirror. All this strategic maneuvering and spending is a big reason shareholders have experienced a wild roller coaster ride. If you can stomach the continued volatility, however, this stock is worth it. Analysts expect Wolfspeed to report 44% sales growth in fiscal 2026, which the company itself believes will be enough to produce breakeven operating cash flow. And management believes the company can swing back to EBITDA profitability during the second half of this year, en route to the return to profitability in fiscal 2027. And longer term, Global Market Insights believes the world's silicon carbide market is likely to grow at a compound annual rate of more than 30% through 2032. But most of this growth is only set to materialize in the latter half of this timeframe when the technology becomes industry-standard. Owning this high potential stock means living with above-average near-term risk. Investors have to remain focused on how well this silicon carbide leader can navigate the industry's long-term potential. The market should start rewarding Wolfspeed's progress toward profitability in the meantime. Should you invest $1,000 in Palo Alto Networks right now? Before you buy stock in Palo Alto Networks, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Palo Alto Networks wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $872,947 !* Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. See the 10 stocks » *Stock Advisor returns as of December 2, 2024 James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics and Wolfspeed. The Motley Fool recommends Gartner and Palo Alto Networks. The Motley Fool has a disclosure policy . 3 Monster Stocks to Hold for the Next 10 Years was originally published by The Motley Fool
